Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs

Shuang Wang1,2, Zhenye Xu1 and Lifang Wang1

1Department of Oncology II, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
2Department of Oncology, Seventh People’s Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China

Correspondence to: Zhenye Xu, email: Zhenyexuxc@sina.com
Lifang Wang, email: 13816927507@139.com

Keywords: cyclophosphamide, lung cancer, myelosuppression, Shuanghuang Shengbai granule, white blood cells

Received: August 15, 2016   Accepted: June 02, 2017   Published: July 10, 2017

Copyright: Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Background: Shuanghuang Shengbai granule is effective in curing cyclophosphamide-induced myelosuppression without promoting lung cancer development. This study aims to investigate its mechanism and therapeutic targets.

Methods: Nude mice with lung cancer were treated with physiological saline (control), cyclophosphamide, or cyclophosphamide + Shuanghuang Shengbai. MicroRNA microarray was used to investigate the differentially expressed microRNAs in lung cancer stem cells or bone marrow hematopoietic stem cells between the three groups. MicroRNA expressions were confirmed using quantitative real-time polymerase chain reaction.

Results: Cyclophosphamide suppressed tumor growth and decreased the ratio of SP+ lung cancer stem cells (P<0.05). Shuanghuang Shengbai further decreased the ratios of SP+ and CD24+IGF1R+ lung cancer stem cells (P<0.05). Shuanghuang Shengbai completely reversed the cyclophosphamide-induced decreases in white blood cells, proliferation index of bone marrow cells, and the ratio of CD34+SCA1+ bone marrow hematopoietic stem cells (P<0.05). We found 45 and 343 altered microRNAs for SP+ lung cancer stem cells and CD34+SCA1+ bone marrow hematopoietic stem cells, respectively. Moreover, miR-32*, miR-466i-5p, and mmu-miR-669c in SP+ lung cancer stem cells were confirmed, as well as mmu-miR-106b*, mmu-miR-144, mmu-miR-669k*, mmu-miR-142-3p, mmu-miR-210, and mmu-miR-223 in CD34+SCA1+ bone marrow hematopoietic stem cells.

Conclusion: Shuanghuang Shengbai might promote the proliferation of CD34+SCA1+ bone marrow hematopoietic stem cells via up-regulating mmu-miR-106b*, mmu-miR-144, and mmu-miR-669k*, as well as down-regulating mmu-miR-142-3p, mmu-miR-210, and mmu-miR-223. Shuanghuang Shengbai might further inhibit the proliferation of SP+ lung cancer stem cells via enhancing the expressions of miR-32*, miR-466i-5p, and mmu-miR-669c. These might be the mechanism and therapeutic targets of Shuanghuang Shengbai granule.
INTRODUCTION

Lung cancer is the most common cancer in men and the leading cause of cancer death in women [1]. The 5-year relative survival of lung cancer is currently 18% [2]. Especially, lung cancer diagnosed in China comprises about 33-50% of the global incidence burden. For lung cancer, 733,300 new cases and 432,400 deaths were estimated to appear in China in 2015 [3]. Cyclophosphamide (CTX) has been widely used to block the progression of lung cancer in clinic [4]. However, CTX generally causes severe acute toxicities like myelosuppression [5]. Once myelosuppression appears, patients are more likely to suffer from infection. Currently, protecting patients from CTX-induced myelosuppression is a main challenge in lung cancer treatment.

Nowadays, colony-stimulating factor, granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor are the main drugs in treating myelosuppression [6, 7]. However, these drugs can lead to lung injury, splenic rupture and vascular events, and they even promote cancer development and metastasis [8, 9]. As a traditional Chinese medicine, Shuanghuang Shengbai (SHSB) granule has been widely used in clinic for decades in China [10]. It can increase white blood cells (WBCs) and cure myelosuppression, whereas it cannot cause obvious adverse effect or cancer progression [11, 12]. Reportedly, SHSB granule can enhance the epidermal growth factor receptor signaling pathway in bone marrow and the Notch signaling pathway in bone marrow nuclear cells [13, 14]. SHSB granule can reduce the percentage of bone marrow cells (BMCs) in G0/G1 phase and increase the proliferation index of BMCs via up-regulating CDK4, CDK6 and cyclin D1 [15]. Also, it promotes the transformation of hematopoietic stem cells from G0/G1 phase to S phase via up-regulating c-Myc, cell division cycle 2A, Rb, pRb and E2F in bone marrow nuclear cells [10]. On the contrary, it inhibits the proliferation of tumor cells in an opposite way [10, 15].

Reportedly, WBCs are mainly differentiated from bone marrow hematopoietic stem cells (BMHSCs; e.g. CD34+SCA1+ BMHSCs). Lung cancer stem cells (LCSCs) are responsible for the initiation, progression, metastasis and relapse of lung cancers (e.g. SP+ LCSCs, CD24+IGF1R+ LCSCs and CD133+ LCSCs) [16, 17]. Therefore, the proliferation and numbers of BMHSCs and LCSCs are critical for myelosuppression and lung cancer. As a kind of non-coding RNAs, microRNAs play crucial roles in cell proliferation via regulating the expression of target genes post-transcriptionally [18, 19]. However, the effect of SHSB granule on LCSCs and BMHSCs and the corresponding mechanism at microRNA level are still unclear.

In the present study, nude mice with lung cancer were treated with physiological saline, CTX, or CTX + SHSB granule. Then, LCSCs ratio and BMHSCs ratio were determined. Microarray analysis was performed to study the microRNA profiling of LCSCs and BMHSCs. MicroRNA expressions were further validated using quantitative real time-polymerase chain reaction (qRT-PCR). Our results might shed light on the mechanism and therapeutic targets of SHSB granule in curing myelosuppression from the aspect of microRNAs.

RESULTS

Tumor mass and general blood indexes

Tumor masses in CTX and CTX+SHSB groups were significantly smaller than that in control group (4-d, 6-d, 8-d and 10-d; P<0.05; Figure 1A). When compared with control group, WBCs were significantly decreased after CTX injection (4-d, 6-d and 8-d; P<0.05; Figure 1B). However, SHSB treatment reversed the CTX-induced decline in WBCs, and the number of WBCs was completely recovered 10 days after SHSB treatment (10-d; Figure 1B). Besides, red blood cells and platelets in the three groups were similar (4-d, 6-d, 8-d and 10-d; Figure 1C and 1D).

Cell cycle and proliferation index

Proliferation index of lung cancer cells in CTX+SHSB group was significantly lower than that in CTX and control groups (4-d, 6-d, 8-d and 10-d; P<0.05; Figure 1E).

Moreover, the proliferation index of BMCs in CTX group was first significantly decreased (4-d; P=0.05) and then increased (6-d, 8-d and 10-d; P<0.05; Figure 1F) in comparison with that in control group. In contrast, the proliferation index of BMCs in CTX+SHSB group was remarkably higher than that in CTX and control groups (8-d and 10-d; P<0.05; Figure 1F).

Ratio of stem cells

SP+ LCSCs ratio was significantly declined after CTX injection and further declined after CTX+SHSB treatment (8-d and 10-d; P<0.05; Figure 1G and Supplementary Figure 1). CD24+IGF1R+ LCSCs ratio in control and CTX groups were similar, whereas it was remarkably decreased after CTX+SHSB treatment (4-d, 6-d, 8-d and 10-d; P<0.05; Figure 1H and Supplementary Figure 1). In addition, CD133+ LCSCs ratio was declined after CTX or CTX+SHSB treatment (4-d and 10-d; P<0.05; Figure 1I and Supplementary Figure 1).

In comparison with control group, CD34+SCA1+ BMHSCs ratio in CTX group was first decreased (4-d and 6-d; P<0.05), then increased (8-d; P=0.05), and finally decreased (10-d; P<0.05) after CTX injection (Figure 1J and Supplementary Figure 1). In contrast, CD34+SCA1+ BMHSCs ratio in CTX+SHSB group was remarkably higher.
than that in CTX group and constantly increased along with the treating time (4-d, 6-d, 8-d and 10-d; P<0.05; Figure 1J and Supplementary Figure 1). These results were consistent with the results of proliferation index of BMCs (Figure 1F).
MicroRNA microarray analysis

MicroRNAs isolated from SP+ LCSCs (8-d) and CD34+SCA1+ BMHSCs (6-d) were analyzed using microarray (miRCURY™ LNA Array, version: 16.0; Figure 2A). Based on Volcano Plot filtering (Figure 2B), 49, 5 and 49 DEmiRNAs in LCSCs were found between CTX and control groups, CTX+SHSB and control groups, as well as CTX+SHSB and CTX groups, respectively (Fold change ≥1.5 and P≤0.05; Figure 2C). A total of 278, 45 and 234 DEmiRNAs in BMHSCs were identified between CTX and control groups, CTX+SHSB and control groups, as well as CTX+SHSB and CTX groups, respectively (Fold change ≥1.5 and P≤0.05; Figure 2C). Furthermore, ANOVA analysis identified 45 DEmiRNAs (in LCSCs) and 343 DEmiRNAs (in BMHSCs) between the three groups (Table 1).

Confirmation of 12 DEmiRNAs

QRT-PCR was performed to confirm the differential expression of 12 DEmiRNAs (Table 2 and Figure 3). As shown in Figure 3, mmu-miR-32* (Figure 3A), mmu-miR-466i-5p (Figure 3B) and mmu-miR-669c (Figure 3C) in SP+ LCSCs were significantly up-regulated after CTX.
### Table 1: DEmiRNAs in LCSCs and BMHSCs

| Cell     | DEmiRNA |
|----------|---------|
| LCSCs    | mmu-miR-3095-3p | mmmiR-669a/o-3p | mmmiR-466f | mmmiR-431 | mmmiR-3081* |
|          | mmu-miR-466a/p-5p | mmmiR-379 | mmmiR-1897-5p | mmmiR-488* | mcmv-miR-M23-2* |
|          | mmmiR-32* | mmmiR-3065* | mmmiR-194-2* | mmmiR-1192 | mmmiR-675-5p |
|          | mmmiR-466a-5p | mmmiR-379 | mmmiR-32* | mmmiR-194 | mmmiR-881 |
|          | mmmiR-466i-5p | mmmiR-379 | mmmiR-466c-5p | mcmv-miR-m01-2 | mmmiR-669l |
|          | mmmiR-34c* | mmmiR-3071 | mmmiR-122* | mmmiR-1187 | mmmiR-291a-5p |
|          | mmmiR-3082-5p | mmmiR-669k* | mmmiR-3067 | mmmiR-669o-5p | mmmiR-669l |
|          | mmmiR-195* | mmmiR-669e | mmmiR-466c-5p | mmmiR-669l | mmmiR-669l |
|          | mmmiR-669f-5p | mmmiR-3078* | mmmiR-466b/o-5p | mmmiR-669n | mmmiR-541* |
|          | mmmiR-669c | mmmiR-706 | mmmiR-466e-5p | mmmiR-669p* | mmmiR-221* |
| BMHSCs   | mmmiR-3103* | mmmiR-194 | mmmiR-669l* | mmmiR-19a | mmmiR-19a |
|          | mmmiR-434-3p | mmmiR-32* | mmmiR-192 | mmmiR-126-5p | mmmiR-126-5p |
|          | mmmiR-467d* | mmmiR-145* | mmmiR-99a | mmmiR-215 | mmmiR-215 |
|          | mmmiR-467b* | mmmiR-762 | mmmiR-374 | mmmiR-681 | mmmiR-681 |
|          | mmmiR-714 | mmmiR-499 | mmmi-let-7c | mmmiR-16-2* | mmmiR-133b |
|          | mmmiR-466i-3p | mmmiR-702 | mmmiR-466a/e-3p | mmmiR-196a-1* | mmmiR-291b-3p |
|          | mmmiR-883a-5p | mmmiR-329* | mmmiR-136 | mmmiR-675-5p | mmmiR-1962 |
|          | mmmiR-3090* | mmmiR-376a | mmmiR-466f-3p | mmmiR-411 | mmmiR-3098-3p |
|          | mmmiR-669d-2* | mmmiR-7b* | mmmiR-142-5p | mmmiR-434-5p | mmmiR-146a |
|          | mmmiR-100 | mmmiR-224 | mmmiR-1946b | mmmiR-1b-5p | mmmiR-496* |
|          | mmmiR-466m-3p | mmmiR-466a/b/c/e/p/n-3p | mmmiR-3086-3p | mmmiR-162-5p | mmmiR-300 |
|          | mmmiR-721 | mmmiR-466n-3p | mmmiR-29a* | mmmiR-1247 | mmmiR-345-5p |
|          | mmmiR-467c* | mmmiR-144 | mmmiR-770-3p | mmmiR-1a-1* | mmmiR-465-5p |
|          | mmmiR-1900 | mmmiR-2861 | mmmiR-34c* | mmmiR-154* | mmmiR-138-2* |
|          | mmmiR-3095-3p | mmmiR-493 | mmmiR-22 | mmmiR-101a | mmmiR-1249 |
|          | mmmiR-23a* | mmmiR-668* | mmmiR-296-3p | mmmiR-106a | mmmiR-877 |
|          | mmmv-miR-m88-1 | mmmiR-470 | mmmiR-29b | mmmiR-24-2* | mmmiR-21* |
|          | mmmiR-3064-5p | mmmiR-146b | mmmiR-669h-3p | mmmiR-185* | mmmiR-669m/666m-5p |
|          | mmmiR-490-3p | mmmiR-292-5p | mmmiR-466l-3p | mmmiR-1931 | mmmiR-703 |
|          | mmmiR-24 | mmmiR-5097 | mmmiR-152 | mmmiR-325* | mmmiR-140 |
|          | mmmiR-467e* | mmmiR-145 | mmmiR-290-3p | mmmiR-344g-5p | mmmiR-15a |
|          | mmmiR-127 | mmmiR-19b | mmmiR-3104-5p | mmmiR-128-2* | mmmiR-328 |
|          | mmmiR-467a* | mmmiR-194-2* | mmmiR-1187 | mmmiR-149 | mmmiR-378 |
|          | mmmiR-29c | mghv-miR-M1-2-3p | mmmiR-125a-3p | mmmiR-706 | mmmiR-450a |
|          | mmmiR-297a*/c*/c*/-297b-3p | mmmiR-92a-2* | mmmiR-132* | mmmiR-1194 | mmmiR-339-5p |
|          | mmmiR-138-1* | mmmiR-218 | mmmiR-224* | mmmiR-365-2* | mmmiR-1949 |

(Continued)
| DEmiRNA       | mmu-miR-669i | mmu-miR-503* | mghv-mir-M1-1* | mmu-miR-142-3p |
|--------------|-------------|-------------|----------------|----------------|
| mghv-miR-M1-5 |             |             |                |                |
| mmmiR-466g   |             |             |                |                |
| mmmiR-27b    |             |             |                |                |
| mmmiR-69d*   |             |             |                |                |
| mmmiR-195*   |             |             |                |                |
| mmmiR-467f   |             |             |                |                |
| mmmiR-1982*  |             |             |                |                |
| mmmiR-669b*  |             |             |                |                |
| mmmiR-710    |             |             |                |                |
| mmmiR-223    |             |             |                |                |
| mmmiR-192    |             |             |                |                |
| mmmiR-465b-5p|             |             |                |                |
| mmmiR-1992   |             |             |                |                |
| mmmiR-298    |             |             |                |                |
| mmmiR-1934   |             |             |                |                |
| mmmiR-1981*  |             |             |                |                |
| mmmiR-669k*  |             |             |                |                |
| mmmiR-669e*  |             |             |                |                |
| mmmiR-206    |             |             |                |                |
| mmmiR-871-3p |             |             |                |                |
| mmmiR-30d    |             |             |                |                |
| mmmiR-1981   |             |             |                |                |
| mmmiR-669e   |             |             |                |                |
| mmmiR-23a    |             |             |                |                |
| mmmiR-433    |             |             |                |                |
| mmmiR-425    |             |             |                |                |

(Continued)
treatment. These microRNAs were further up-regulated after CTX+SHSB treatment. These results demonstrated that CTX promoted the expression of these microRNAs in SP^+ LCSCs, and SHSB further strengthened their expression.

**Table 2: Primers for miRNA qRT-PCR**

| miRNA  | RT (Primer)                                                                 | PCR (Forward primer)    | PCR (Reverse primer)    |
|--------|------------------------------------------------------------------------------|-------------------------|-------------------------|
| mir-144| GTCGTATCCAGTCAGGGTGTCGAGGTTACGAGTACAGTACA                                     | CGGCCCGGCTACAGTAA        | GTGACGAGGTTCGGAGGT      |
| mir-106b*| GTCGTATCCAGTCAGGGTGTCGAGGTTACGAGTACAGCAGCA                                  | AATGCGCGCTGTGGA          | GTGACGAGGTTCGGAGGT      |
| mir-669k*| GTCGTATCCAGTCAGGGTGTCGAGGTTACGAGTACACGC                                      | GCCCGGTGTGCGCATG         | GTGACGAGGTTCGGAGGT      |
| mir-142-3p| GTCGTATCCAGTCAGGGTGTCGAGGTTACGAGTACACGAC                                      | GCGCTGTAGTGTTTTCTACTT    | GTGACGAGGTTCGGAGGT      |
| mir-223| GTCGTATCCAGTCAGGGTGTCGAGGTTACGAGTACACGAC                                      | CCACCGGTGTGCATG           | GTGACGAGGTTCGGAGGT      |
| mir-210| GTCGTATCCAGTCAGGGTGTCGAGGTTACGAGTACACGAC                                      | AATCTGTTGCGGTGTA         | GTGACGAGGTTCGGAGGT      |
| mir-32*| GTCGTATCCAGTCAGGGTGTCGAGGTTACGAGTACACGAC                                      | CGGGCGGCAATTTACGG        | GTGACGAGGTTCGGAGGT      |
| mir-669C| GTCGTATCCAGTCAGGGTGTCGAGGTTACGAGTACACGAC                                      | CGCCCATAGGTGTTGG         | GTGACGAGGTTCGGAGGT      |
| mir-466i-5p| GTCGTATCCAGTCAGGGTGTCGAGGTTACGAGTACACGAC                                      | CGCCCTGTTGTTGCTG         | GTGACGAGGTTCGGAGGT      |
| mir-122*| GTCGTATCCAGTCAGGGTGTCGAGGTTACGAGTACACGAC                                      | CGCCCATAGGTGTTGG         | GTGACGAGGTTCGGAGGT      |
| mir-34C*| GTCGTATCCAGTCAGGGTGTCGAGGTTACGAGTACACGAC                                      | GCCCAATCCTACACGACACACAC | GTGACGAGGTTCGGAGGT      |
| mir-541*| GTCGTATCCAGTCAGGGTGTCGAGGTTACGAGTACACGAC                                      | ACACCCGTGCAAGGCAACGCAACTG | GTGACGAGGTTCGGAGGT      |
| U6     | CTGCCTTCGCCAGCAAGTGTCGAGGTTACGAGTACAGTACA                                      | AACGCTTCACGAAATTTGCCT    | GTGACGAGGTTCGGAGGT      |

DEmiRNAs in bold were confirmed using qRT-PCR. DEmiRNAs: differentially expressed microRNAs; LCSCs: lung cancer stem cells; BMHSCs: bone marrow hematopoietic stem cells; CTX: cyclophosphamide; SHSB: Shuanghuang Shengbai; ANOVA: analysis of variance; qRT-PCR: quantitative real time-polymerase chain reaction.
In addition, mmu-miR-106b* (Figure 3G), mmu-miR-144 (Figure 3H) and mmu-miR-669k* (Figure 3I) in CD34+ SCA1+ BMHSCs were down-regulated after CTX treatment. However, these microRNAs were up-regulated after CTX+SHSB treatment. On the contrary, mmu-miR-142-3p (Figure 3J), mmu-miR-210 (Figure 3K) and mmu-miR-223 (Figure 3L) in CD34+ SCA1+ BMHSCs were up-regulated after CTX treatment. These microRNAs were down-regulated after CTX+SHSB treatment. These results indicated that SHSB reversed the effects of CTX on microRNAs like mmu-miR-106b*, mmu-miR-144, mmu-miR-669k*, mmu-miR-142-3p, mmu-miR-210 and mmu-miR-223 in CD34+ SCA1+ BMHSCs.

DISCUSSION

CTX frequently causes myelosuppression [5], and SHSB granule can cure myelosuppression without
promoting the development of lung cancer [11, 12]. However, its mechanism and therapeutic targets are still unclear.

In this study, CTX treatment strongly suppressed tumor growth (Figure 1A). CTX decreased SP+ LCSCs ratio (Figure 1G) and CD133+ LCSCs ratio (Figure 1I). Reportedly, alkylating units in the CTX-derived phosphoramid mustard in human can alkylate DNA [20], and CTX induces cell apoptosis [21, 22]. Our results were consistent with the suppressive effects of CTX on lung cancer [4]. These results also suggested that CTX might suppress lung cancer growth via decreasing SP+ LCSCs and CD133+ LCSCs.

More importantly, proliferation index of lung cancer cells (Figure 1E), SP+ LCSCs ratio (Figure 1G) and CD24+IGFR+ LCSCs ratio (Figure 1H) in CTX+SHSB group were remarkably lower than that in control and CTX groups. These results agreed well with the inhibitory effects of SHSB on the transformation of lung cancer cells from G0/G1 phase to S phase [10]. Also, these results indicated that SHSB granule might suppress the growth of lung cancer via decreasing SP+ LCSCs.

In the present study, CTX remarkably reduced the number of WBCs (Figure 1B). This result was consistent with the fact that CTX could cause myelosuppression [5]. After CTX treatment, declines were found in the proliferation index of BMCs (4-d; Figure 1F) and CD34+SCA1+ BMHSCs ratio (Figure 1J). This suggested that CTX might cause myelosuppression via inhibiting the proliferation of CD34+SCA1+ BMHSCs. In contrast, SHSB granule completely reversed the decrease in WBCs (Figure 1B). This agreed well with the fact that SHSB could cure myelosuppression [10-12]. Especially, SHSB remarkably increased the proliferation index of BMCs (Figure 1F) and CD34+SCA1+ BMHSCs ratio (Figure 1J). As WBCs derived from BMHSCs, our results indicated that SHSB might increase WBCs via promoting the proliferation of CD34+SCA1+ BMHSCs.

As shown in qRT-PCR results, CTX enhanced the expression of mmu-miR-32*, mmu-miR-466i-5p and mmu-miR-669c in SP+ LCSCs, and SHSB granule further strengthened their expression (Figure 3A–3C). Reportedly, miR-32 is located at 9q31.2 in a region of homozygous deletion in various types of cancer [23]. For instance, it promotes the growth, migration and invasion of colorectal carcinoma cells [24]. Currently, little is known about the role of miR-466i-5p in cancer development. Ionizing radiation can induce apoptosis in cochlea hair cells, and miR-466i-5p in HEI-OC1 cells is significantly up-regulated 12, 24 and 48h after ionizing radiation [25]. MiR-669c is significantly down-regulated in mice with Bronchiolo-alveolar adenocarcinoma [26]. In this study, the up-regulations of miR-32*, miR-466i-5p and mmu-miR-669c in SP+ LCSCs after CTX treatment were consistent with previous studies [23, 25, 26]. Besides, these microRNAs were further up-regulated after CTX+SHSB treatment. This indicated that SHSB might further inhibit SP+ LCSCs proliferation via enhancing the expressions of miR-32*, miR-466i-5p and mmu-miR-669c.

Moreover, CTX significantly changed the expressions of mmu-miR-106b* (down-regulation), mmu-miR-144 (down-regulation), mmu-miR-669k* (down-regulation), mmu-miR-142-3p (up-regulation), mmu-miR-210 (up-regulation) and mmu-miR-223 (up-regulation) in CD34+SCA1+ BMHSCs (Figure 3G–3L). However, SHSB reversed the effects of CTX on these microRNAs (Figure 3G–3L). Among these microRNAs, little is known about the role of miR-106b*, mmu-miR-144 and miR-669k* in proliferation or differentiation of hematopoietic stem cells [27, 28]. In contrast, miR-142a-3p accelerates the formation and differentiation of hematopoietic stem cells [29]. MiR-210 level is increased in CD34+ cells in myelodysplastic syndromes, a disease caused by abnormal proliferation and differentiation of hematopoietic stem cells [30]. MiR-223 is preferentially expressed in bone marrow [31], and it induces human granulopoiesis [32]. Therefore, SHSB might enhance BMHSCs proliferation via up-regulating mmu-miR-106b*, mmu-miR-144 and mmu-miR-669k*, as well as down-regulating mmu-miR-142-3p, mmu-miR-210 and mmu-miR-223.

MATERIALS AND METHODS

Animals, cell line, and lung cancer models

Nude mice are immune deficient, and tumor can be easily established in them. Therefore, four-week old male BALB/C nude mice weighted 20±2g were purchased from Shanghai Laboratory Animal Center of Chinese Academy of Sciences [Batch Number: SCXK (Shanghai) 2007-0005]. These mice were bred in the Specific-Pathogen-Free animal laboratory of Longhua Hospital (Shanghai, China) under a condition of 24-26°C, 65-70% humidity and free access to diet and water.

Lung adenocarcinoma is one of the main kinds of lung cancer, and A549 is a cell line of human lung adenocarcinoma. In this study, A549 was obtained from the Shanghai Cell Bank of Chinese Academy of Sciences. A549 cells were cultured in F12k medium supplemented of lung cancer, and A549 is a cell line of human lung adenocarcinoma. In this study, A549 cells were cultured in F12k medium supplemented with 10% fetal bovine serum (Gibco, NY, USA). Then, 0.2 ml 1×10^7/ml A549 cells with high proliferating activity were inoculated into the oxters of nude mice. Lung cancer models were successfully constructed four weeks after inoculation.

Animal grouping and drug administration

The constructed cancer models were randomly divided into three groups, including control group (N=36), CTX group (i.e. CTX group; N=36), and CTX + SHSB granule group (i.e. CTX+SHSB group; N=36).
Since CTX could lead to obvious myelosuppression, we utilized CTX to treat lung cancer to establish a mice model of myelosuppression. CTX was generated from Jiangsu Hengrui Medicine Co., Ltd (Batch Number: H32020857). Before usage, 1 mg/ml CTX was freshly prepared using physiological saline. SHSB granule was obtained from the drug preparation center of Longhua Hospital (Batch Number: Z05170773). SHSB granule was dissolved in double-distilled H$_2$O to generate a 2 g/ml SHSB solution. Nude mice in control group were intraperitoneally injected with physiological saline (100 mg/kg/d) for three days, and these mice also took physiological saline (40 g/kg/d) via gastroenteric irrigation for 10 days. Nude mice in CTX group were intraperitoneally injected with CTX (100 mg/kg/d) for three days, and these mice also took physiological saline (40 g/kg/d) via gastroenteric irrigation for 10 days. Intrapерitoneal injection and gastroenteric irrigation were started at the same day for all mice. All the animal experiments were approved by the Animal Ethics Committee of Shanghai Longhua Hospital, China.

**General blood indexes and tumor mass**

Eyeball was removed, and peripheral blood was taken from mice 4, 6, 8 or 10 days after intraperitoneal injection. WBCs, red blood cells and platelets were counted using an automatic blood cell analyzer (DxH 800™; Beckman Coulter Inc., Miami, FL, USA). Thereafter, mice were sacrificed by cutting off their neck under anesthesia. Xenograft tumors were obtained and weighted under a sterile and RNAase-free condition.

**Generation of lung cancer cells and BMCs**

Lung cancer cells were generated from xenograft tumor (4-d, 6-d, 8-d and 10-d) after trypsin digestion. The femur and tibia were taken from the sacrificed mice (4-d, 6-d, 8-d and 10-d) and sterilized using 75% alcohol. BMCs were obtained after splitting and opening the femur and tibia. Then, 2 ml hemolysin was added into BMCs (6-d), respectively. For each sample, total RNA was isolated using Trizol Reagent (Invitrogen; CA, USA), and microRNA was purified using miRNeasy mini kit (Qiagen; Valencia, CA, USA). RNA quantity and quality were determined using NanoDrop spectrophotometer (ND-1000; Nano-Drop Technologies; DE, USA). Thereafter, the miRCURY™ Hy3™/Hy5™ Power labeling kit (Exiqon; Vedbaek, Denmark) was utilized to label 1 ng microRNA to miRCURY™ LNA Array (version: 16.0).

**MicroRNA microarray analysis**

Flow cytometry was used to isolate SP$^+$ LCSCs and CD34$^+$ SCAs$^+$ BMHSCs from lung cancer cells (8-d) and BMCs (6-d), respectively. For each sample, total RNA was isolated using Trizol Reagent (Invitrogen; CA, USA), and microRNA was purified using miRNeasy mini kit (Qiagen; Valencia, CA, USA). RNA quantity and quality were determined using NanoDrop spectrophotometer (ND-1000; Nano-Drop Technologies; DE, USA). Thereafter, the miRCURY™ Hy3™/Hy5™ Power labeling kit (Exiqon; Vedbaek, Denmark) was utilized to label 1 ng microRNA to miRCURY™ LNA Array (version: 16.0).

**Ratio of stem cells**

For each sample of lung cancer cells (500 μl, 2×10$^6$/ml), 10 μl Hoechst 33342/Propidium iodide solution was added to mark SP$^+$ LCSCs; 10 μl Anti-CD24 labeled with allophycocyanin and 20 μl Anti-IGF1R labeled with phycoerythrin were added to mark CD24$^+$ IGF1R$^+$ LCSCs; 20 μl Anti-CD133 labeled with allophycocyanin and 20 μl Anti-SCA1 labeled with phycoerythrin were added to mark CD34$^+$ SCA1$^+$ BMHSCs. Flow cytometry was used to detect the ratios of these stem cells.

**MicroRNA microarray analysis**

Flow cytometry was used to isolate SP$^+$ LCSCs and CD34$^+$ SCAs$^+$ BMHSCs from lung cancer cells (8-d) and BMCs (6-d), respectively. For each sample, total RNA was isolated using Trizol Reagent (Invitrogen; CA, USA), and microRNA was purified using miRNeasy mini kit (Qiagen; Valencia, CA, USA). RNA quantity and quality were determined using NanoDrop spectrophotometer (ND-1000; Nano-Drop Technologies; DE, USA). Thereafter, the miRCURY™ Hy3™/Hy5™ Power labeling kit (Exiqon; Vedbaek, Denmark) was utilized to label 1 ng microRNA to miRCURY™ LNA Array (version: 16.0).

**Microarray data were normalized using the Quantile method. Differentially expressed microRNAs (DEmiRNAs) between groups were identified via Volcano Plot filtering [criteria: Fold change ≥1.5 and P≤0.05] and analysis of variance (ANOVA; criterion: P≤0.05). Moreover, hierarchical clustering was conducted using the MeV software (v4.6; the institute for genomic research; http://www.tm4.org/mev.html) to determine the specificity of DEmiRNAs between groups.**

**qRT-PCR**

A total of 12 DEmiRNAs were randomly selected, and their relative levels were detected. Total RNA was isolated from SP$^+$ LCSCs (4-d, 6-d, 8-d and 10-d) and
CD34<sup>+</sup>SCA1<sup>+</sup>BMHSCs (4-d, 6-d, 8-d and 10-d) using Trizol Reagent (Invitrogen). Reverse transcription was conducted in a 20 μl reaction system (condition: 37°C for 15 min and then 85°C for 5 s) using PrimeScript RT reagent kit (TaKaRa Biotechnology Co. Ltd.; Dalian, China). Thereafter, RT-PCR was performed in a 20 μl reaction system [condition: 95°C for 5 min, 40 cycle (95°C for 10 s, 60°C for 20 s, 72°C for 20 s, and 79°C for 20 s)] using the SYBR Premix Ex Taq kit (TaKaRa) and a PCR instrument (Rotor Gene 3000; Corbett Research; Sydney, Australia). Relative levels of these microRNAs were calculated using 2<sup>ΔΔCT</sup> method and U6 levels.

**Statistical analysis**

All data were shown in a “mean ± standard deviation” manner and analyzed using Statistical Product and Service Solutions (SPSS; version: 18.0) software. Differences between groups were determined using one-way ANOVA method. Least-Significant-Difference test was utilized under a condition of equal variance. Otherwise, Dunnett’s T3 method was used to adjust results. The threshold for statistical difference was set as P<0.05.

**CONCLUSION**

To sum up, SHSB granule might cure CTX-induced myelosuppression and increase WBCs via enhancing CD34<sup>+</sup>SCA1<sup>+</sup>BMHSCs proliferation (SHSB granule up-regulated the expressions of mmu-miR-106b*, mmu-miR-144 and mmu-miR-669k*, as well as down-regulated the expressions of mmu-miR-142-3p, mmu-miR-210 and mmu-miR-223 in CD34<sup>+</sup>SCA1<sup>+</sup>BMHSCs). Besides, SHSB granule might also suppress lung cancer progression via inhibiting SP<sup>+</sup>LCSCs proliferation (SHSB granule up-regulated miR-32*, miR-466i-5p and mmu-miR-669c in SP<sup>+</sup>LCSCs). These findings might help us to better understand the mechanism of SHSB in curing myelosuppression and blocking lung cancer development. Our results might also provide potential therapeutic targets for treating CTX-caused myelosuppression in patients with lung cancer.

**Limitation**

In the present study, microRNA profiling was only determined in SP<sup>+</sup>LCSCs (8-d) and CD34<sup>+</sup>SCA1<sup>+</sup>BMHSCs (6-d). A time-course microRNA profiling analysis might provide more information. Only the change patterns of 12 microRNAs were detected by using qRT-PCR. Much more microRNAs will be selected to perform qRT-PCR in our future study.

**Author contributions**

ZX participated in the design of this study. LW collected important background information and performed the statistical analysis. SW performed experiments and drafted the manuscript. ZL and LW reviewed the manuscript. All authors read and approved the final manuscript.

**ACKNOWLEDGMENTS**

This work was supported by National Nature Science Foundation of China (No. 30973822; Project name: The research of dual-regulation effect of Shuanghuang Shengbai Granule on both hematopoietic stem cells and lung cancer stem cells’ proliferation and differentiation), Shanghai Pudong district Science and Technology Development Fund, Innovation Fund (health care) project (No. PKJ2015-Y14; Project name: Mechanism of feiyanning decoction regulate on SP<sup>+</sup> lung cancer stem cells’ proliferation and differentiation by mediating Wnt/β-catenin signaling pathway), Reserve business experts (foster) program of Shanghai university of traditional Chinese medicine (No. ZQHZ201601), and Talents Training Program of Shanghai Seventh People’s Hospital (Grant No. XX2015-02).

**CONFLICTS OF INTEREST**

The authors declare no potential conflicts of interest.

**REFERENCES**

The authors declare no potential conflicts of interest.

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5-29.
3. Chen WQ, Zheng RS, Baade PD, Zhang SW, Zeng HM, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66:115-132.
4. Johnson DH, Einhorn LH, Birch R, Vollmer R, Perez C, Krauss S, Omura G, Greco FA. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1987; 5:1731-1738.
5. Neboh EE, Ufelle SA. Myeloprotective activity of crude methanolic leaf extract of Cassia occidentalis in cyclophosphamide-induced bone marrow suppression in Wistar rats. Adv Biomed Res. 2015; 4:5.
6. Choi MR, Solid CA, Chia VM, Blaes AH, Page JH, Barron R, Arneson TJ. Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy. Support Care Cancer. 2014; 22:1619-1628.
7. Barni S, Lorusso V, Giordano M, Sogno G, Gamucci T, Santoro A, Passalacqua R, Iaffaioli V, Zilembo N, Mencoboni M, Roselli M, Pappagallo G, Pronzato P. A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol. 2014; 31:797.

8. Hung JY, Horn D, Woodruff K, Prihoda T, LeSaux C, Peters J, Tio F, Abboud-Werner SL. Colony-stimulating factor 1 potentiates lung cancer bone metastasis. Lab Invest. 2014; 94:371-381.

9. Gu X, Xu ZY, Zhu LY, Wang LF, Li K, Pei Q. Dual control of Shuanghuang Shengbai granule on upstream and downstream signal modulators of CyclinD-CDK4/6 signaling pathway of cell cycle in Lewis-bearing mice with cyclophosphamide-induced myelosuppression. Onco Targets Ther. 2013; 6:199-209.

10. Xu ZY, Zhu YW, Zhou WD, Zhang H, Ju YF, Zhao LH, Deng HB, Wu J, Shen DY, Zhang HX. Clinical observation on effect of shuanghuang shengbai granule on chemotherapy induced myelosuppression in tumor patients and on ultrastructure of bone marrow in mice. Chin J Integr Med Tradit West Medicine. 2001; 7:277-282.

11. Wang HT, Wan LF, Xu ZH, Kang XF, Si HL, Ruan MY. Shuanghuang Shengbai granule regulates the EGFR signaling pathway in bone marrow of mice with myelosuppression induced by chemotherapy. Shanghai J Tradit Chin Med. 2003; 44:919-921.

12. Wang LF, Xu ZY, Si HL, Wang ZQ, Deng HB, Su W, Jin GY. Shuanghuang Shengbai granule dually regulates the Notch signaling pathway in bone marrow nuclear cells of Lewis mice with lung cancer and myelosuppression induced by chemotherapy. J Shanghai Univers Tradit Chin Med. 2015; 49:53.

13. Wang LF, Xu ZY, Jin CJ, Sha HF, Wang ZQ, Zhou WD, Zhang M, Wu J, Bai B. Dual regulation of cell cycles by Shuanghuang Shengbai granule in Lewis-bearing mice with chemotherapy-induced myelosuppression and its mechanism. Zhong Xi Yi Jie He Xue Bao. 2009; 7:453-457.

14. Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN. Cancer stem cells in lung cancer: evidence and controversies. Respiratory. 2013; 18:757-764.

15. Eramo A, Lotti F, Sette G, Pilozzi E, Biffioni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008; 15:504-514.

16. Song SJ, Ito K, Ala U, Kats L, Webster K, Sun SM, Jongen-Lavrencic M, Manova-Todorova K, Teruya-Feldstein J, Avigan DE, Delwel R, Pandolfi PP. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell. 2013; 13:87-101.

17. Garofalo M, Croce CM. Role of microRNAs in maintaining cancer stem cells. Adv Drug Deliv Rev. 2015; 81:53-61.

18. Ferreira SG, Peliciari-Garcia RA, Takahashi-Hyodo SA, Rodrigues AC, Amaral FG, Berra CM, Bordin S, Curi R, Cipolla-Neto J. Effects of melatonin on DNA damage induced by cyclophosphamide in rats. Braz J Med Biol Res. 2013; 46:278-286.

19. Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol. 2001; 60:1268-1279.

20. Hughes FM Jr, Croag AG, Nimmich AR, Pratt-Thomas JD, Purves JT. Cyclophosphamide induces an early wave of acrolein-independent apoptosis in the urothelium. Adv Biosci Biotechnol. 2013; 4.

21. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Nat Acad Sci U S A. 2004; 101:2999-3004.

22. Wu W, Yang J, Feng X, Wang H, Ye S, Yang P, Tan W, Wei G, Zhou Y. MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer. 2013; 12:30.

23. Tan PX, Du SS, Ren C, Yao QW, Zheng R, Li R, Yuan YW. MicroRNA-207 enhances radiation-induced apoptosis by directly targeting Akt3 in cochlea hair cells. Cell Death Dis. 2014; 5:e1433.

24. Snyder-Talkington BN, Dong C, Sargent LM, Porter DW, Staska LM, Hubbs AF, Raese R, McKinney W, Chen BT, Battelli L, Lowry DT, Reynolds SH, Castranova V, et al. mRNAs and miRNAs in whole blood associated with lung hyperplasia, fibrosis, and bronchiolo-alveolar adenoma and adenocarcinoma after multi-walled carbon nanotube inhalation exposure in mice. J Appl Toxicol. 2016; 36:161-174.

25. Bueno MJ, Perez de Castro I, Malumbres M. Control of cell proliferation pathways by microRNAs. Cell Cycle. 2008; 7:3143-3148.

26. Zhang LY, Ho-Fun Lee V, Wong AM, Kwong DL, Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY, Fu L. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis. 2013; 34:454-463.
29. Lu X, Li X, He Q, Gao J, Gao Y, Liu B, Liu F. miR-142-3p regulates the formation and differentiation of hematopoietic stem cells in vertebrates. Cell Res. 2013; 23:1356-1368.

30. Lee DW, Futami M, Carroll M, Feng Y, Wang Z, Fernandez M, Whichard Z, Chen Y, Kornblau S, Shpall EJ, Bueso-Ramos CE, Corey SJ. Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene. 2012; 31:4085-4094.

31. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004; 303:83-86.

32. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, Bozzi I. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBP alpha regulates human granulopoiesis. Cell. 2005; 123:819-831.